Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elzovantinib
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Elzovantinib is an orally bioavailable, small molecule, macrocyclic multi-targeted tyrosine kinase inhibitor that potently inhibits MET (c-Met), SRC, and CSF1R kinases. It disrupts signaling pathways involved in tumor cell proliferation, survival, invasion, metastasis, and immune suppression within the tumor microenvironment. Elzovantinib is being developed for the treatment of advanced solid tumors with genetic alterations in MET and has received FDA Fast Track designation for MET-amplified advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma after prior chemotherapy. It also holds Orphan Drug designation for gastric cancer including gastroesophageal junction adenocarcinoma. The drug is currently under clinical investigation in multiple cancers including non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, hepatocellular carcinoma, and other solid tumors.
- Other names
- elzovantinibElzovantinib [INN]
02
Targets
SFK (SRC family kinases)CSF1R (Macrophage colony-stimulating factor receptor)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on elzovantinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elzovantinib.